SG10202010155YA - Compositions and methods for making antibodies based on use of expression-enhancing loci - Google Patents
Compositions and methods for making antibodies based on use of expression-enhancing lociInfo
- Publication number
- SG10202010155YA SG10202010155YA SG10202010155YA SG10202010155YA SG10202010155YA SG 10202010155Y A SG10202010155Y A SG 10202010155YA SG 10202010155Y A SG10202010155Y A SG 10202010155YA SG 10202010155Y A SG10202010155Y A SG 10202010155YA SG 10202010155Y A SG10202010155Y A SG 10202010155YA
- Authority
- SG
- Singapore
- Prior art keywords
- expression
- compositions
- methods
- antibodies based
- making antibodies
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Reproductive Health (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662325400P | 2016-04-20 | 2016-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202010155YA true SG10202010155YA (en) | 2020-11-27 |
Family
ID=58701851
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202010155YA SG10202010155YA (en) | 2016-04-20 | 2017-04-20 | Compositions and methods for making antibodies based on use of expression-enhancing loci |
| SG11201807885PA SG11201807885PA (en) | 2016-04-20 | 2017-04-20 | Compositions and methods for making antibodies based on use of expression-enhancing loci |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807885PA SG11201807885PA (en) | 2016-04-20 | 2017-04-20 | Compositions and methods for making antibodies based on use of expression-enhancing loci |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11512144B2 (OSRAM) |
| EP (1) | EP3445781A1 (OSRAM) |
| JP (3) | JP7096770B2 (OSRAM) |
| KR (1) | KR102547738B1 (OSRAM) |
| CN (2) | CN109195986B (OSRAM) |
| AR (1) | AR109451A1 (OSRAM) |
| AU (2) | AU2017253241B2 (OSRAM) |
| BR (1) | BR112018071283A2 (OSRAM) |
| CA (1) | CA3015389A1 (OSRAM) |
| EA (1) | EA201892010A1 (OSRAM) |
| IL (2) | IL314779A (OSRAM) |
| MX (2) | MX2018012868A (OSRAM) |
| SG (2) | SG10202010155YA (OSRAM) |
| TW (2) | TW202415767A (OSRAM) |
| WO (1) | WO2017184832A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018071283A2 (pt) * | 2016-04-20 | 2019-02-12 | Regeneron Pharma | célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno. |
| IL275462B1 (en) * | 2017-12-22 | 2025-09-01 | Genentech Inc | Targeted integration of nucleic acids |
| CN113631711B (zh) * | 2018-12-21 | 2025-03-04 | 豪夫迈·罗氏有限公司 | 核酸的靶向整合 |
| WO2020204055A1 (ja) * | 2019-04-02 | 2020-10-08 | 中外製薬株式会社 | 標的特異的な外来遺伝子の導入方法 |
| CN114080454A (zh) | 2019-06-26 | 2022-02-22 | 豪夫迈·罗氏有限公司 | 核酸的随机化构型靶向整合 |
| TW202323529A (zh) | 2021-10-18 | 2023-06-16 | 美商再生元醫藥公司 | 包括腺病毒相關病毒聚核苷酸的真核細胞 |
| CA3235566A1 (en) | 2021-10-18 | 2023-04-27 | Michael Goren | Mammalian cells comprising integrated cas9 genes to produce stable integration sites, and mammalian cells comprising stable integration sites and other sites |
| AU2022371200A1 (en) | 2021-10-18 | 2024-05-02 | Regeneron Pharmaceuticals, Inc. | Controlled transcription of polynucleotides |
| KR20240117146A (ko) * | 2021-12-22 | 2024-07-31 | 제넨테크, 인크. | 다중 벡터 재조합효소 매개 카세트 교환 |
| US20250361524A1 (en) * | 2022-06-10 | 2025-11-27 | Fujifilm Diosynth Biotechnologies Uk Limited | Method for producing cells, method for producing heteromultimeric protein, method for producing bispecific antibody, and method for producing vector set, mammalian cells, CHO cells, and cell pool |
| WO2025054526A1 (en) | 2023-09-07 | 2025-03-13 | Regeneron Pharmaceuticals, Inc. | Production and purification of covalently surface modified adeno-associated virus |
| WO2025111473A1 (en) | 2023-11-21 | 2025-05-30 | Regeneron Pharmaceuticals, Inc. | Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6800457B2 (en) | 1998-09-22 | 2004-10-05 | Bristol-Myers Squibb Company | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
| US6406863B1 (en) | 2000-06-23 | 2002-06-18 | Genetastix Corporation | High throughput generation and screening of fully human antibody repertoire in yeast |
| DK1531666T3 (da) | 2002-05-29 | 2014-01-13 | Regeneron Pharma | Inducerbart eukaryot-ekspressionssystem |
| JP2006512061A (ja) | 2002-11-14 | 2006-04-13 | ジェネンテック・インコーポレーテッド | イントロン融合コンストラクトおよび高発現産生細胞系を選択するための使用方法 |
| DK3050963T3 (da) | 2005-03-31 | 2019-12-09 | Chugai Pharmaceutical Co Ltd | Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement |
| EP1999154B1 (en) | 2006-03-24 | 2012-10-24 | Merck Patent GmbH | Engineered heterodimeric protein domains |
| NZ573557A (en) | 2006-06-02 | 2010-08-27 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| JP2010514416A (ja) | 2006-12-21 | 2010-05-06 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規な方法 |
| WO2008089396A1 (en) | 2007-01-19 | 2008-07-24 | Invitrogen Corporation | Compositions and methods for genetic manipulation and monitoring of cell lines |
| CA2681974C (en) | 2007-03-29 | 2019-12-31 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| WO2008151219A1 (en) | 2007-06-04 | 2008-12-11 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
| WO2009089004A1 (en) | 2008-01-07 | 2009-07-16 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| ES2661074T3 (es) | 2009-06-02 | 2018-03-27 | Regeneron Pharmaceuticals, Inc. | Células deficientes de fucosilación |
| SI2975051T1 (sl) | 2009-06-26 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | Zlahka izolirana bispecifična protitelesa z nativnim imunoglobulinskim formatom |
| AU2010296018B2 (en) | 2009-09-16 | 2016-05-05 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
| AU2010297011A1 (en) | 2009-09-18 | 2012-04-12 | Selexis S.A. | Products and methods for enhanced transgene expression and processing |
| PL2560993T3 (pl) | 2010-04-20 | 2024-11-04 | Genmab A/S | Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania |
| PL2606064T3 (pl) | 2010-08-16 | 2015-07-31 | Novimmune Sa | Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał |
| TWI641687B (zh) | 2012-05-29 | 2018-11-21 | 美商再生元醫藥公司 | 生產細胞株增強子 |
| EP2711428A1 (en) * | 2012-09-21 | 2014-03-26 | Lonza Biologics plc. | Site-specific integration |
| US20150203591A1 (en) * | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI745610B (zh) | 2012-11-14 | 2021-11-11 | 美商再生元醫藥公司 | 重組細胞表面捕捉蛋白質 |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
| TWI728373B (zh) | 2013-12-23 | 2021-05-21 | 美商建南德克公司 | 抗體及使用方法 |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| AU2015335921B2 (en) | 2014-10-23 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Novel CHO integration sites and uses thereof |
| AU2016325630B2 (en) | 2015-09-23 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Optimized anti-CD3 bispecific antibodies and uses thereof |
| BR112018071283A2 (pt) * | 2016-04-20 | 2019-02-12 | Regeneron Pharma | célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno. |
-
2017
- 2017-04-20 BR BR112018071283A patent/BR112018071283A2/pt unknown
- 2017-04-20 SG SG10202010155YA patent/SG10202010155YA/en unknown
- 2017-04-20 KR KR1020187029365A patent/KR102547738B1/ko active Active
- 2017-04-20 CN CN201780024557.0A patent/CN109195986B/zh active Active
- 2017-04-20 EP EP17723183.4A patent/EP3445781A1/en active Pending
- 2017-04-20 US US16/095,084 patent/US11512144B2/en active Active
- 2017-04-20 EA EA201892010A patent/EA201892010A1/ru unknown
- 2017-04-20 WO PCT/US2017/028555 patent/WO2017184832A1/en not_active Ceased
- 2017-04-20 TW TW112130927A patent/TW202415767A/zh unknown
- 2017-04-20 CN CN202211606177.7A patent/CN116515757A/zh active Pending
- 2017-04-20 AR ARP170101019A patent/AR109451A1/es unknown
- 2017-04-20 MX MX2018012868A patent/MX2018012868A/es unknown
- 2017-04-20 CA CA3015389A patent/CA3015389A1/en active Pending
- 2017-04-20 JP JP2018552794A patent/JP7096770B2/ja active Active
- 2017-04-20 SG SG11201807885PA patent/SG11201807885PA/en unknown
- 2017-04-20 IL IL314779A patent/IL314779A/en unknown
- 2017-04-20 IL IL262266A patent/IL262266B2/en unknown
- 2017-04-20 TW TW106113298A patent/TWI827531B/zh active
- 2017-04-20 AU AU2017253241A patent/AU2017253241B2/en active Active
-
2018
- 2018-10-19 MX MX2025003852A patent/MX2025003852A/es unknown
-
2021
- 2021-07-09 JP JP2021114374A patent/JP2021164479A/ja active Pending
-
2022
- 2022-09-28 US US17/936,059 patent/US20230130799A1/en active Pending
-
2023
- 2023-11-29 JP JP2023201924A patent/JP7781128B2/ja active Active
-
2024
- 2024-09-26 AU AU2024220124A patent/AU2024220124A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289046A (en) | Preparations and methods for inhibiting antigens of a certain lineage | |
| IL262268A (en) | Preparations and methods for the preparation of antibodies based on the use of an amplified expression locus | |
| SG10202010155YA (en) | Compositions and methods for making antibodies based on use of expression-enhancing loci | |
| IL265844A (en) | Anti-lag-3 antibodies and preparations | |
| IL266918A (en) | Anti-ctla-4 antibodies and methods of using them | |
| IL262176A (en) | Anti-tim-3 antibodies and preparations | |
| IL265800A (en) | Anti-lag-3 antibodies and methods of using them | |
| IL256295A (en) | Anti-ntb-a antibodies and related compositions and methods | |
| ZA201701244B (en) | Carrier-antibody compositions and methods of making and using the same | |
| SG10201913500TA (en) | Anti-ctla-4 antibodies and methods of use thereof | |
| IL265957A (en) | Anti-c1s antibodies and methods of using them | |
| IL259681A (en) | New antibodies against claudin and methods of using them | |
| EP3166892A4 (en) | Scale-inhibition compositions and methods of making and using the same | |
| GB2542309B (en) | Systems and methods for analyzing the characteristics and compositions of cement additives | |
| PT3113774T (pt) | Composições de grapiprant e métodos de utilização das mesmas | |
| PL3445730T3 (pl) | Makrokompozyty i kompozycje z kamienia i szkła oraz sposoby wytwarzania | |
| IL251588A0 (en) | Methods and preparations for increasing the potency of antifungal agents | |
| GB201620828D0 (en) | Compositions of antibody construct-agonist conjugates and methods thereof | |
| HK1262029A1 (en) | Compositions and methods for making antibodies based on use of expression-enhancing loci | |
| HK1261744A1 (en) | Compositions and methods for making antibodies based on use of an expression-enhancing locus | |
| ZA201606358B (en) | Compositions of selenoorganic compounds and methods and methods of use thereof | |
| HK1261040A1 (en) | Composition of antibody construct-agonist conjugates and methods of use thereof |